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Abstract 
Chronic neuroleptic treatment induces an increase in the density of D2 dopamine receptors in the striatum. The effect of prolonged administration 
of haloperidol on mRNA levels of the short (D,J and long (DzL) isoforms of the D, dopamine receptor and the D, dopamine receptor in different 
brain regions was examined. Haloperidol caused a significant rise in both D,, and D,, mRNA levels in the striatum, but had no effect on D, mRNA 
levels. This rise was restricted to the striatum, showing that the effect of haloperidol on dopamine receptor mRNA is both subtype- and tissue-specific. 
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1. Introduction 
Dopaminergic pathways in the brain have for some 
time been associated with a number of neurological dis- 
orders, such as schizophrenia, Parkinson’s disease and 
Huntington’s chorea [l]. The treatment of schizophrenia 
by the administration of neuroleptic drugs is frequently 
complicated by the development of a hyperkinetic move- 
ment disorder termed tardive dyskinesia. This is thought 
to be the result of a supersensitivity of dopamine recep- 
tors induced by chronic neuroleptic treatment, and has 
been associated with an increase in D2 dopamine recep- 
tor binding 123. While the effect of neuroleptics such as 
haloperidol has been associated with dopamine receptors 
of the D2 subclass** (i.e. DZ, D3 and D,, in the striatum, 
most studies at the mRNA level have concentrated on 
the D, receptor subtype and have been performed on the 
striatum and pituitary gland [3-61. Little is known of 
whether haloperidol acts similarly on long and short 
isoforms of the D, receptor or of whether it affects the 
mRNA levels of the more recently cloned D, [7,8] or D, 
[9] dopamine receptors. We were interested in investigat- 
ing whether the effect of haloperidol can be observed in 
brain regions other than the striatum, and in gaining 
more information about the subtype-specificity of its ac- 
*Corresponding author. Fax: (972) (8) 341 411. 
**To avoid confusion of nomenclature, the terms Dl and D2 shall be 
used to refer to the two classes of dopamine receptor originally defined 
by pharmacological and biochemical studies at the protein level. The 
cloned receptor subtypes, detined by their DNA sequence, shall be 
denoted by a subscript, e.g. D,. 
tion. We have therefore taken advantage of oligonucleo- 
tide probes which can distinguish between the long and 
short isoforms of the murine D2 dopamine receptor, and 
a cDNA probe specific for the murine D, receptor in 
order to observe the effect of chronic haloperidol treat- 
ment on mRNA levels of D, and D3 receptors in different 
regions of the mouse brain. 
2. Materials and methods 
2.1. Animals and tissue preparation 
30 Balblc mice (20-25 g) were injected i.p. daily with 4 mg/kg halo- 
peridol for 16 days. Control mice received an equivalent volume (0.5 ml) 
of vehicle (PBS, pH 6.5). Three days after the last injection mice were 
sacrificed and brain regions were dissected out and frozen immediately 
in liquid nitrogen for RNA preparation. Tissue from each brain region 
was pooled for haloperidol-treated and control mice, and was used for 
RNA preparation. Whole brains were taken from two mice from each 
group to be used for membrane preparation and [‘Hlspiperone binding 
as previously described [lo]. 
2.2 Labelling of oligonucleotides and riboprobes 
Two antisense oligonucleotides were synthesised according to the 
sequence of the mouse D, dopamine receptor [ll]. The D,,-specific 
probe was based on a sequence from the 87-bp insert (5’- 
CTCCGCCTGTTCACTGGGAAACTCCCATTAG-3’). The D,,- 
specific probe was based on the 15 nucleotides flanking the 87-bp insert 
(5’~CGGCGGGCAGCATCCTTGAGTGGTGTCTTC-33. The speci- 
ficity of these probes for the respective subtypes was determined by 
Northern analysis using RNA prepared from DIL and D2s stably trans- 
fected cell lines. The /3-actin probe was based on exon 5 of the human 
/3-actin sequence (S-TGCCACCAGACAGCACTGTGTTGG-3’). Ol- 
igonucleotides were labelled at their 5’ termini using T4 polynucleotide 
kinase and [Y-~~P]ATP. For riboprobe preparation, a 293-bp PCR 
product from the putative 3rd cytoplasmic loop of the mouse D, 
dopamine receptor was generated as described previously [8], subcloned 
into the EcoRI site of pBluescript (Stratagene), and linearised with 
BarnHI. Transcription was carried out according to manufacturer’s 
instructions using T3 RNA polymerase (Boehringer Mannheim). 
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2.3. RNA preparation and Northern analysis 
Total RNA was prepared from different brain regions according to 
the guanidium thiocyanate-caesium chloride method [12]. 20 pg total 
RNA (striatum, elf. tubercle) or 30yg total RNA (other brain regions) 
was electrophoresed on a 1% formaldehyde-agarose g l, and blotted 
onto nylon membranes (‘Qiabrane’, Qiagen). Northern blots were 
hybridised as described previously [8], and densitometric analysis of 
autoradiograms was performed using a Molecular Dynamics 300A 
Computing Densitometer with the ImageQuant Software to get volume 
integration. 
2.4 RNase protection analysis 
RNase protection analysis was performed using the enzyme RNase 
ONE (Promega) according to manufacturer’s instructions. Briefly, 30 
pg sample RNA was hybridised with lo5 cpm of riboprobe overnight 
at 48”C, and was then RNase digested for 35 min at room temperature 
using 1 ml RNase ONE. Digested samples were precipitated in the 
presence of 10 pg carrier yeast tRNA and were run on a 6% poly- 
acrylamide17 M urea sequencing el. The gel was dried before overnight 
exposure to autoradiography at -80°C. 
3. Results 
one binding may be the consequence of increased mRNA 
levels of more than one subtype of dopamine receptor. 
Since Northern analysis is not sufficiently sensitive to 
detect the low levels of D, receptor mRNA, we used 
RNase protection analysis on total RNA from haloperi- 
dol-treated and control mice in order to investigate 
whether haloperidol influences D, receptor mRNA ex- 
pression. Using a probe from the putative third cytoplas- 
mic loop of the D, receptor, a specific signal was ob- 
served at approximately 285 bp (Fig. 3, arrow), which 
was not present in control embryo RNA or the carrier 
yeast tRNA. In contrast to the D, receptor, the D3 recep- 
tor mRNA levels did not change upon haloperidol treat- 
ment in the striatum. nor was any change observed in 
tissues where the D, receptor is more highly expressed, 
such as the olfactory tubercle and olfactory bulb (Fig. 3). 
It should be noted that the lower D,-specific band may 
represent he shorter D3 isoform (D3S), and that this also 
shows no change upon haloperidol treatment. 
To confirm that the haloperidol treatment had been 
effective in increasing dopamine receptor protein levels, 
binding assays using [3H]spiperone were performed on 
membranes prepared from two treated and two control 
mice. A 25-35% rise in D2 dopamine receptor levels was 
observed (data not shown), in accordance with previous 
studies [2]. In order to determine whether the increase in 
dopamine receptor levels was widespread or whether it 
showed tissue-specificity, Northern blots of RNA from 
different brain regions of haloperidol-treated and con- 
trol mice were hybridised with an oligonucleotide spe- 
cific for the long isoform of the D2 receptor, which pro- 
duces a band at 2.9 kb. A 2.4-fold (2.42 + 0.26) increase 
in DzL mRNA levels was observed in the striatum (Fig. 
l), as quantitated by densitometric scanning. However, 
this change in D2,_ mRNA levels was confined to the 
striatum, with no change occurring in other D,-express- 
ing tissues such as olfactory tubercle, hypothalamus, 
brainstem, olfactory bulb (Fig. 2) and cortex (data not 
shown). Hybridisation with a /3-actin probe produced no 
change in /?-actin mRNA levels between haloperidol- 
treated and control animals (Figs. 1 and 2), confirming 
that the effect observed in the striatum was specific to 
D,, mRNA and was not the result of a general increase 
in striatal transcription. 
4. Discussion 
The effect of haloperidol in increasing dopamine re- 
ceptor levels has previously been studied at the level of 
the protein using radioligand binding assays. More re- 
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In order to determine whether haloperidol also influ- 
ences expression of the short D, isoform, a D,,-specific 
oligonucleotide was hybridised to the same, de-probed, 
Northern blots. As with the D,, isoform, a greater than 
2-fold (2.2 f 0.4) increase in D,, mRNA levels was ob- 
served in the striatum in haloperidol-treated mice (Fig. 
l), with no change occurring in the any other tissues 
(data not shown). 
b DZL D2s P-actin 
Since spiperone also binds with high affinity to other 
members of the D2 dopamine receptor subclass, it is 
possible that the haloperidol-induced rise in [3H]spiper- 
Fig. 1. Northern analysis showing the effect of haloperidol treatment 
on DZL and Dzs receptor mRNA levels in striatum. (a) Northern blot 
analysis was performed on total RNA from the striatum of haloperidol- 
treated (H) and control (C) mice. Hybridisation was performed with a 
D,,-specific oligonucleotide probe (left), a D,,.specific oligonucleotlde 
probe (centre) or a p-actin specific oligonucleotide probe (right). The 
position of the 18 S and 28 S ribosomal bands are indicated. (b) Den- 
sitometric scanning was performed on Northern blots to quantitate the 
increase in mRNA levels induced by haloperidol (black) compared with 
control (hatched) levels. The data analysed was obtained from three 
independent experiments. 
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Fig. 2. Northern analysis showing the effect of haloperidol treatment 
on D,, and D, receptor mRNA levels in various brain regions. North- 
em blot analysis was performed on total RNA from various brain 
regions of haloperidol-treated (H) and control (C) mice. Hybridisation 
was performed with a D,,-specific oligonucleotide probe (upper panel) 
or a ,&actin specific oligonucleotide probe (lower panel). Lanes repre- 
senting olfactory tubercle were exposed to autoradiography overnight; 
other lanes were exposed for 5 nights. The position of the 18 S and 28 S 
ribosomal bands are indicated. (OT) olfactory tubercle, (HT) hy~thal- 
amus, (BS) brainstem, (OB) olfactory bulb, (CB) cerebellum. 
cently, its effect on the expression of dopamine receptor 
mRNA has been investigated by a number of groups. 
While most studies to date have been performed on rats, 
we have based our system on mice, and have included 
reiatively large numbers in order to diminish the effect 
of individual differences. 
We have shown here that the action of the neuroleptic 
haloperidol in raising Dz mRNA levels is exclusive in the 
brain to the striatum, and that it is effective on both the 
long and short Dz receptor isoforms to the same degree. 
This activity, however, is not extended to the D, dopam- 
ine receptor, at which haloperidol is also known to dis- 
play potent antagonist activity. 
While some groups have found no change in D2 
mRNA levels upon haloperidol treatment [13,14], there 
are several studies which do show a correlation between 
neuroleptic treatment and an increase in striatal D, re- 
ceptor mRNA levels [4-6,151. In addition, Martres et al. 
[is] see no overall change in D, receptor mRNA levels 
in the cortex or pens-medulla using a probe common to 
the long and short D, isoforms, in agreement with our 
findings that Dz mRNA levels did not change in any 
tissue other than the striatum. Furthermore, the 2-fold 
increase reported by Buckland et al. [16] in DzL and D2s 
mRNA levels in whole brain most probably arises from 
the selective increase in the striatum reported here. 
The evidence presented in this study suggests that ha- 
loperidol acts differentially at the D, and D, dopamine 
receptor subtypes, but that it acts equally at the short 
and long isoforms of each receptor. The finding that D, 
receptor mRNA levels do not change upon halo~ridol 
treatment is supported by a recent study using in situ 
hybridisation on D, receptor mRNA in the nucleus ac- 
cumbens [17], which shows no change in the quantity or 
distribution of D, receptor transcripts upon haloperidol 
treatment in rats. 
The mechanism by which haloperidol produces its ef- 
fect is not clear. It appears, however, that it is the antag- 
onist activity of haloperidol at D, receptors which is 
connected with its ability to augment D, mRNA levels. 
A rise in striatal D, mRNA has been found to be induced 
by other D2 antagonists in addition to haloperidol, such 
as sulpiride [6], while studies in the pituitary gland show 
that agonists at D2 receptors uch as bromocriptine have 
no such effect [3]. However, although receptor blockade 
appears to be related to the increase in D, dopamine 
receptor concentration, there seem to be other factors 
involved. Haloperidol also acts as a strong antagonist at 
D, receptors, but these levels are not augmented follow- 
ing neuroleptic treatment. In addition, haloperidol acts 
as an antagonist at D, receptors throughout the brain, 
whereas we have shown here that only in the striatum 
does this lead to upregulation of D, receptor mRNA. It 
remains to be determined what other factors play a role 
in determining the tissue- and subtype-specificity of the 
response to haloperidol treatment. 
The haloperidol induced rise in D, mRNA levels may 
be mediated either at the transcriptional evel or post- 
transcriptionally, for example by increasing mRNA 
stability. The notion that an increase in transcriptional 
activity is involved is supported by evidence that halo- 
peridol can increase mRNA levels of the transcription 
factor c-fos and that this activity is mediated by D2 
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Fig. 3. RNase protection analysis showing the effect of haloperidol 
treatment on D, receptor mRNA levels. RNase protection analysis was 
performed on total RNA from different brain regions of haloperidol- 
treated (H) and control (C) mice, using a cRNA probe prepared from 
a PCR product representing the third cytoplasmic loop of the D, 
dopamine receptor (see section 2). Arrow indicates the position of the 
specific D, mRNA band. (ST) striatum, (OT) olfactory tubercle, (OB) 
olfactory bulb, (E) embryo, (t) tRNA. 
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receptors, since it is inhibited by the D2 agonist 
LY 171555 and mimicked by the D2 antagonist (+) bu- 
taclamol [18]. It will be interesting to observe what other 
transcription factors emerge as being involved in con- 
trolling the expression of D2 receptors, and whether they 
act similarly on both short and long isoforms of the D? 
receptor. An improved understanding of the control of 
dopamine receptor gene expression is essential for the 
development of highly specific drugs which can be used 
in the treatment of dopamine receptor-related neurolog- 
ical disorders. 
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